Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552990 | 0.90 | CHEK2 (0.88) | CHEK2 | |
| SCHEMBL5641933 | 0.89 | CHEK2 (0.75) | CHEK2 | |
| SCHEMBL1553001 | 0.89 | CHEK2 (0.70) | CHEK2 | |
| SCHEMBL1552338 | 0.86 | CHEK2 (0.88) | CHEK2 | |
| SCHEMBL1552315 | 0.86 | CHEK2 (0.88) | CHEK2PRMT5 | |
| SCHEMBL5643450 | 0.82 | CHEK2 (0.75) | CHEK2 | |
| SCHEMBL1551663 | 0.81 | CHEK2 (0.70) | CHEK2 | |
| SCHEMBL1552275 | 0.81 | CHEK2 (0.89) | CHEK2 | |
| SCHEMBL1552257 | 0.81 | CHEK2 (0.89) | CHEK2 | |
| SCHEMBL1552780 | 0.81 | CHEK2 (0.88) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824832-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | claimed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | claimed |
| WO-2006004791-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | WO | claimed |
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-01-05 | — | — | US | claimed |
| EP-1824832-B1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-27 | — | — | EP | disclosed |
| EP-1824832-B1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-27 | — | — | EP | disclosed |
| EP-1824832-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250427-B2 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| WO-2006004791-A1 | ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHERS AS ANTI-CANCER AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004039-A1 | Aryl-substituted benzimidazole and imidazopyridine ethers | WEE1, CDKN1A, DDB1 | CHEK2 27/4885PRMT5 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.